Michelle L Giles1, Marin C Zapata2, Stephen T Wright3, Kathy Petoumenos3, Miriam Grotowski4, Jennifer Broom5, Matthew G Law3, Catherine C O'Connor2. 1. Department of Infectious Diseases, Monash University, Clayton, Vic. 3168, Australia. 2. RPA Sexual Health, Sydney Local Health District, Sydney, NSW 2050, Australia. 3. The Kirby Institute, UNSW Australia, Sydney, NSW 2052, Australia. 4. Tamworth Sexual Health Service, Tamworth, NSW 2340, Australia. 5. Department of Medicine, Nambour Hospital, Nambour, Qld 4560, Australia.
Abstract
UNLABELLED: Background Gender differences vary across geographical settings and are poorly reported in the literature. The aim of this study was to evaluate demographics and clinical characteristics of participants from the Australian HIV Observational Database (AHOD), and to explore any differences between females and males in the rate of new clinical outcomes, as well as initial immunological and virological response to antiretroviral therapy. METHODS: Time to a new clinical end-point, all-cause mortality and/or AIDS illness was analysed using standard survival methods. Univariate and covariate adjusted Cox proportional hazard models were used to evaluate the time to plasma viral load suppression in all patients that initiated antiretroviral therapy (ART) and time to switching from a first-line ART to a second-line ART regimen. RESULTS: There was no significant difference between females and males for the hazard of all-cause mortality [adjusted hazard ratio: 0.98 (0.51, 1.55), P=0.67], new AIDS illness [adjusted hazard ratio: 0.75 (0.38, 1.48), P=0.41] or a composite end-point [adjusted hazard ratio: 0.74 (0.45, 1.21), P=0.23]. Incident rates of all-cause mortality were similar between females and males; 1.14 (0.61, 1.95) vs 1.28 (1.12, 1.45) per 100 person years. Virological response to ART was similar for females and males when measured as time to viral suppression and/or time to virological failure. CONCLUSION: This study supports current Australian HIV clinical care as providing equivalent standards of care for male and female HIV-positive patients. Future studies should compare ART-associated toxicity differences between ART-associated toxicity differences between men and women living with HIV in Australia.
UNLABELLED: Background Gender differences vary across geographical settings and are poorly reported in the literature. The aim of this study was to evaluate demographics and clinical characteristics of participants from the Australian HIV Observational Database (AHOD), and to explore any differences between females and males in the rate of new clinical outcomes, as well as initial immunological and virological response to antiretroviral therapy. METHODS: Time to a new clinical end-point, all-cause mortality and/or AIDS illness was analysed using standard survival methods. Univariate and covariate adjusted Cox proportional hazard models were used to evaluate the time to plasma viral load suppression in all patients that initiated antiretroviral therapy (ART) and time to switching from a first-line ART to a second-line ART regimen. RESULTS: There was no significant difference between females and males for the hazard of all-cause mortality [adjusted hazard ratio: 0.98 (0.51, 1.55), P=0.67], new AIDS illness [adjusted hazard ratio: 0.75 (0.38, 1.48), P=0.41] or a composite end-point [adjusted hazard ratio: 0.74 (0.45, 1.21), P=0.23]. Incident rates of all-cause mortality were similar between females and males; 1.14 (0.61, 1.95) vs 1.28 (1.12, 1.45) per 100 person years. Virological response to ART was similar for females and males when measured as time to viral suppression and/or time to virological failure. CONCLUSION: This study supports current Australian HIV clinical care as providing equivalent standards of care for male and female HIV-positivepatients. Future studies should compare ART-associated toxicity differences between ART-associated toxicity differences between men and women living with HIV in Australia.
Authors: Guoxing Greg Soon; Min Min; Kimberly A Struble; Kirk M Chan-Tack; Thomas Hammerstrom; Karen Qi; Susan Zhou; Rafia Bhore; Jeffrey S Murray; Debra B Birnkrant Journal: AIDS Patient Care STDS Date: 2012-06-26 Impact factor: 5.078
Authors: S J Bersoff-Matcha; W C Miller; J A Aberg; C van Der Horst; H J Hamrick; W G Powderly; L M Mundy Journal: Clin Infect Dis Date: 2000-12-13 Impact factor: 9.079
Authors: Judith Currier; Dawn Averitt Bridge; Debbie Hagins; Carmen D Zorrilla; Judith Feinberg; Robert Ryan; Ron Falcon; Alan Tennenberg; Joseph Mrus; Kathleen Squires Journal: Ann Intern Med Date: 2010-09-21 Impact factor: 25.391
Authors: Mardge H Cohen; Audrey L French; Lorie Benning; Andrea Kovacs; Kathryn Anastos; Mary Young; Howard Minkoff; Nancy A Hessol Journal: Am J Med Date: 2002-08-01 Impact factor: 4.965
Authors: Dawn K Smith; Lytt I Gardner; Ruby Phelps; Merle E Hamburger; Charles Carpenter; Robert S Klein; Ann Rompalo; Paula Schuman; Scott D Holmberg Journal: J Urban Health Date: 2003-12 Impact factor: 3.671
Authors: Shirin Heidari; Mirjam J Eckert; Susan Kippax; Quarraisha Abdool Karim; Papa Salif Sow; Mark A Wainberg Journal: J Int AIDS Soc Date: 2011-03-08 Impact factor: 5.396
Authors: Quarraisha Abdool Karim; Judith D Auerbach; Simone E Buitendijk; Pedro Cahn; Mirjam J Curno; Catherine Hankins; Elly Katabira; Susan Kippax; Richard Marlink; Joan Marsh; Ana Marusic; Heidi M Nass; Julio Montaner; Elizabeth Pollitzer; Maria Teresa Ruiz-Cantero; Lorraine Sherr; Papa Salif Sow; Kathleen Squires; Mark A Wainberg; Shirin Heidari Journal: J Int AIDS Soc Date: 2012-03-08 Impact factor: 5.396
Authors: Michelle L Giles; Amit C Achhra; Alison G Abraham; Andreas D Haas; Michael John Gill; Man Po Lee; Marco Luque; Catherine McGowan; Morna Cornell; Paula Braitstein; Nathalie de Rekeneire; Renaud Becquet; Kara Wools-Kaloustian; Matthew Law Journal: J Int AIDS Soc Date: 2018-06 Impact factor: 5.396